BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Modlin I, Hunt R, Malfertheiner P, Moayyedi P, Quigley E, Tytgat G, Tack J, Heading R, Holtman G, Moss S. Diagnosis and Management of Non-Erosive Reflux Disease – The Vevey NERD Consensus Group. Digestion 2009;80:74-88. [DOI: 10.1159/000219365] [Cited by in Crossref: 87] [Cited by in F6Publishing: 78] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Di Pierro F, Gatti M, Rapacioli G, Ivaldi L. Outcomes in patients with nonerosive reflux disease treated with a proton pump inhibitor and alginic acid ± glycyrrhetinic acid and anthocyanosides. Clin Exp Gastroenterol 2013;6:27-33. [PMID: 23569394 DOI: 10.2147/CEG.S42512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Budzyński J, Pulkowski G, Suppan K, Fabisiak J, Majer M, Kłopocka M, Galus-Pulkowska B, Wasielewski M. Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey. Health Qual Life Outcomes 2011;9:77. [PMID: 21939510 DOI: 10.1186/1477-7525-9-77] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
3 Wang W, Uedo N, Yang Y, Peng L, Bai D, Lu Z, Fan K, Wang J, Wang X, Zhao Y. Autofluorescence imaging endoscopy for predicting acid reflux in patients with gastroesophageal reflux disease. J Gastroenterol Hepatol. 2014;29:1442-1448. [PMID: 25587615 DOI: 10.1111/jgh.12566] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
4 Forcelini CM, Tomiozzo JC Jr, Farré R, Van Oudenhove L, Callegari-Jacques SM, Ribeiro M, Madalosso BH, Fornari F. Effect of nortriptyline on brain responses to painful esophageal acid infusion in patients with non-erosive reflux disease. Neurogastroenterol Motil 2014;26:187-95. [PMID: 24188252 DOI: 10.1111/nmo.12251] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
5 de Bortoli N, Tolone S, Frazzoni M, Martinucci I, Sgherri G, Albano E, Ceccarelli L, Stasi C, Bellini M, Savarino V, Savarino EV, Marchi S. Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. Ann Gastroenterol 2018;31:639-48. [PMID: 30386113 DOI: 10.20524/aog.2018.0314] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
6 Takeuchi T, Takahashi Y, Kawaguchi S, Ota K, Harada S, Kojima Y, Sakamoto H, Kuramoto T, Kojima K, Sanomura M, Hoshimoto M, Higashino T, Itabashi T, Takada K, Sakaguchi M, Tominaga K, Kusano M, Higuchi K. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor. J Gastroenterol Hepatol 2018;33:623-30. [PMID: 28865098 DOI: 10.1111/jgh.13970] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
7 Tsukanov VV, Kasparov EV, Onuchina EV, Vasyutin AV, Butorin NN, Amelchugova OS, Tonkikh YL. [The frequency and clinical aspects of extraesophageal syndromes in elderly patients with gastroesophageal reflux disease]. Ter Arkh 2016;88:28-32. [PMID: 27030180 DOI: 10.17116/terarkh201688228-32] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Langella C, Naviglio D, Marino M, Calogero A, Gallo M. New food approaches to reduce and/or eliminate increased gastric acidity related to gastroesophageal pathologies. Nutrition 2018;54:26-32. [PMID: 29729504 DOI: 10.1016/j.nut.2018.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
9 Gill RS, Collins JS, Talley NJ. Management of noncardiac chest pain in women. Womens Health (Lond) 2012;8:131-43; quiz 144-5. [PMID: 22375717 DOI: 10.2217/whe.12.3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Mari A, Mahamid M, Khoury T. Is it time to recommend water load test before Nissen fundoplication? Minerva Gastroenterol Dietol 2020;66:8-10. [PMID: 32283881 DOI: 10.23736/S1121-421X.20.02678-1] [Reference Citation Analysis]
11 Hunt RH, Scarpignato C. Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease? Clin Transl Gastroenterol 2015;6:e119. [PMID: 26513137 DOI: 10.1038/ctg.2015.39] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
12 Weijenborg PW, Cremonini F, Smout AJ, Bredenoord AJ. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012;24:747-757, e350. [PMID: 22309489 DOI: 10.1111/j.1365-2982.2012.01888.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 76] [Article Influence: 8.8] [Reference Citation Analysis]
13 Huerta-Iga FM, Tamayo-de la Cuesta JL, Noble-Lugo A, Remes-Troche JM, Valdovinos-Díaz MA, Carmona-Sánchez RI; el Grupo Mexicano para el Estudio de la Enfermedad por Reflujo Gastroesofágico 2011. [The Mexican consensus on gastroesophageal reflux disease. Part I]. Rev Gastroenterol Mex 2012;77:193-213. [PMID: 23153413 DOI: 10.1016/j.rgmx.2012.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Savarino V, Pace F, Scarpignato C; Esoxx Study Group. Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease - efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation. Aliment Pharmacol Ther 2017;45:631-42. [PMID: 28116754 DOI: 10.1111/apt.13914] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
15 Mihara H, Boudaka A, Tominaga M, Sugiyama T. Transient Receptor Potential Vanilloid 4 Regulation of Adenosine Triphosphate Release by the Adenosine Triphosphate Transporter Vesicular Nucleotide Transporter, a Novel Therapeutic Target for Gastrointestinal Baroreception and Chronic Inflammation. Digestion. 2020;101:6-11. [PMID: 31770754 DOI: 10.1159/000504021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
16 Alecci U, Bonina F, Bonina A, Rizza L, Inferrera S, Mannucci C, Calapai G. Efficacy and Safety of a Natural Remedy for the Treatment of Gastroesophageal Reflux: A Double-Blinded Randomized-Controlled Study. Evid Based Complement Alternat Med 2016;2016:2581461. [PMID: 27818697 DOI: 10.1155/2016/2581461] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
17 Craig OF, Quigley EM. Current and emerging therapies for the management of functional gastrointestinal disorders. Ther Adv Chronic Dis 2011;2:87-99. [PMID: 23251744 DOI: 10.1177/2040622310389507] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
18 Kamal AN, Clarke JO, Oors JM, Smout AJ, Bredenoord AJ. The Role of Symptom Association Analysis in Gastroesophageal Reflux Testing. Am J Gastroenterol. 2020;115:1950-1959. [PMID: 32740077 DOI: 10.14309/ajg.0000000000000754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Bresadola V, Adani GL, Londero F, Leo CA, Cherchi V, Lorenzin D, Rossetto A, Vit G, Baccarani U, Terrosu G, Anna DD. Non-erosive and uncomplicated erosive reflux diseases: Difference in physiopathological and symptom pattern. World J Gastrointest Pathophysiol 2011; 2(3): 42-48 [PMID: 21860835 DOI: 10.4291/wjgp.v2.i3.42] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
20 Brown AF, Cullen L, Than M. Future developments in chest pain diagnosis and management. Med Clin North Am 2010;94:375-400. [PMID: 20380961 DOI: 10.1016/j.mcna.2010.01.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
21 Smout AJ, Bredenoord AJ. GERD: A challenge to our view of reflux oesophagitis pathogenesis. Nat Rev Gastroenterol Hepatol 2016;13:504-5. [PMID: 27407046 DOI: 10.1038/nrgastro.2016.106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Zhang J, Che H, Zhang B, Zhang C, Zhou B, Ji H, Xie J, Shi X, Li X, Wang F, Tang X. JianpiQinghua granule reduced PPI dosage in patients with nonerosive reflux disease: A multicenter, randomized, double-blind, double-dummy, noninferiority study. Phytomedicine 2021;88:153584. [PMID: 34119741 DOI: 10.1016/j.phymed.2021.153584] [Reference Citation Analysis]
23 Meuret AE, Tunnell N, Roque A. Anxiety Disorders and Medical Comorbidity: Treatment Implications. Adv Exp Med Biol 2020;1191:237-61. [PMID: 32002933 DOI: 10.1007/978-981-32-9705-0_15] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
24 Scarpignato C, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179. [PMID: 27825371 DOI: 10.1186/s12916-016-0718-z] [Cited by in Crossref: 148] [Cited by in F6Publishing: 123] [Article Influence: 24.7] [Reference Citation Analysis]
25 de Bortoli N, Martinucci I, Savarino EV, Frazzoni M, Tutuian R, Tolone S, Piaggi P, Furnari M, Russo S, Bertani L, Macchia L, Savarino V, Marchi S. Manually calculated oesophageal bolus clearance time increases in parallel with reflux severity at impedance-pH monitoring. Dig Liver Dis 2015;47:1027-32. [PMID: 26362613 DOI: 10.1016/j.dld.2015.08.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
26 Kandulski A, Malfertheiner P. Gastroesophageal reflux disease--from reflux episodes to mucosal inflammation. Nat Rev Gastroenterol Hepatol. 2012;9:15-22. [PMID: 22105108 DOI: 10.1038/nrgastro.2011.210] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
27 Eherer AJ, Netolitzky F, Högenauer C, Puschnig G, Hinterleitner TA, Scheidl S, Kraxner W, Krejs GJ, Hoffmann KM. Positive effect of abdominal breathing exercise on gastroesophageal reflux disease: a randomized, controlled study. Am J Gastroenterol. 2012;107:372-378. [PMID: 22146488 DOI: 10.1038/ajg.2011.420] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 4.5] [Reference Citation Analysis]
28 Matsuzaki J, Suzuki H, Iwasaki E, Yokoyama H, Sugino Y, Hibi T. Serum lipid levels are positively associated with non-erosive reflux disease, but not with functional heartburn. Neurogastroenterol Motil. 2010;22:965-70, e251. [PMID: 20482701 DOI: 10.1111/j.1365-2982.2010.01518.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
29 Cho JH, Yoon H, Shin CM, Park YS, Kim N, Lee DH. Efficacy of DA-5204 (Stillen 2X) for patients with gastroesophageal reflux disease: A randomized, double-blind, placebo-controlled pilot study. Medicine (Baltimore) 2020;99:e22729. [PMID: 33126310 DOI: 10.1097/MD.0000000000022729] [Reference Citation Analysis]
30 Kusano M, Hosaka H, Kawamura O, Kawada A, Kuribayashi S, Shimoyama Y, Yasuoka H, Mizuide M, Tomizawa T, Sagawa T, Sato K, Yamada M. More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy. J Gastroenterol 2015;50:298-304. [PMID: 24919745 DOI: 10.1007/s00535-014-0972-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
31 Ratier JC, Pizzichini E, Pizzichini M. Gastroesophageal reflux disease and airway hyperresponsiveness: concomitance beyond the realm of chance? J Bras Pneumol 2011;37:680-8. [PMID: 22042402 DOI: 10.1590/s1806-37132011000500017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
32 Patel D, Fass R, Vaezi M. Untangling Nonerosive Reflux Disease From Functional Heartburn. Clin Gastroenterol Hepatol 2021;19:1314-26. [PMID: 32246998 DOI: 10.1016/j.cgh.2020.03.057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Kalach N, Huvenne H, Gosset P, Papadopoulos S, Dehecq E, Decoster A, Creusy C, Dupont C. Eosinophil counts in upper digestive mucosa of Western European children: variations with age, organs, symptoms, Helicobacter pylori status, and pathological findings. J Pediatr Gastroenterol Nutr. 2011;52:175-182. [PMID: 20890222 DOI: 10.1097/mpg.0b013e3181e2ae00] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
34 Ribolsi M, Giordano A, Guarino MPL, Tullio A, Cicala M. New classifications of gastroesophageal reflux disease: an improvement for patient management? Expert Review of Gastroenterology & Hepatology 2019;13:761-9. [DOI: 10.1080/17474124.2019.1645596] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Limsrivilai J, Charatcharoenwitthaya P, Pausawasdi N, Leelakusolvong S. Imipramine for Treatment of Esophageal Hypersensitivity and Functional Heartburn: A Randomized Placebo-Controlled Trial. Am J Gastroenterol 2016;111:217-24. [PMID: 26753892 DOI: 10.1038/ajg.2015.413] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
36 de Bortoli N, Martinucci I, Savarino E, Bellini M, Bredenoord AJ, Franchi R, Bertani L, Furnari M, Savarino V, Blandizzi C. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they? Neurogastroenterol Motil. 2014;26:28-35. [PMID: 23992024 DOI: 10.1111/nmo.12221] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 6.4] [Reference Citation Analysis]
37 Pardon NA, Vicario M, Vanheel H, Vanuytsel T, Ceulemans LJ, Vieth M, Jimenez M, Tack J, Farré R. A weakly acidic solution containing deoxycholic acid induces esophageal epithelial apoptosis and impairs integrity in an in vivo perfusion rabbit model. Am J Physiol Gastrointest Liver Physiol 2016;310:G487-96. [PMID: 26797397 DOI: 10.1152/ajpgi.00370.2015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
38 Scarpignato C, Hunt RH. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Current Opinion in Gastroenterology 2019;35:344-55. [DOI: 10.1097/mog.0000000000000543] [Cited by in Crossref: 12] [Article Influence: 4.0] [Reference Citation Analysis]
39 Silva RO, Bingana RD, Sales TMAL, Moreira RLR, Costa DVS, Sales KMO, Brito GAC, Santos AA, Souza MÂN, Soares PMG, Sifrim D, Souza MHLP. Role of TRPV1 receptor in inflammation and impairment of esophageal mucosal integrity in a murine model of nonerosive reflux disease. Neurogastroenterol Motil 2018;30:e13340. [DOI: 10.1111/nmo.13340] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
40 Scarpignato C, Gatta L. Acid Suppression for Management of Gastroesophageal Reflux Disease: Benefits and Risks. In: Morice AH, Dettmar PW, editors. Reflux Aspiration and Lung Disease. Cham: Springer International Publishing; 2018. pp. 269-91. [DOI: 10.1007/978-3-319-90525-9_23] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Jung HK, Hong SJ, Jo YJ, Jeon SW, Cho YK, Lee KJ, Lee JS, Park HJ, Shin ES, Lee SH. [Updated guidelines 2012 for gastroesophageal reflux disease]. Korean J Gastroenterol. 2012;60:195-218. [PMID: 23089906 DOI: 10.4166/kjg.2012.60.4.195] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
42 Triantos C, Koukias N, Karamanolis G, Thomopoulos K. Changes in the esophageal mucosa of patients with non erosive reflux disease: How far have we gone? World J Gastroenterol 2015;21:5762-7. [PMID: 26019440 DOI: 10.3748/wjg.v21.i19.5762] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
43 Gaddam S, Wani S, Ahmed H, Maddur P, Hall SB, Gupta N, Puli SR, Higbee A, Rastogi A, Bansal A, Sharma P. The impact of pre-endoscopy proton pump inhibitor use on the classification of non-erosive reflux disease and erosive oesophagitis: The impact of PPI use on NERD classification. Alimentary Pharmacology & Therapeutics 2010;32:1266-74. [DOI: 10.1111/j.1365-2036.2010.04468.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
44 Lee JH, Cho YK, Jeon SW, Kim JH, Kim NY, Lee JS, Bak YT; Korean Society of Neurogastroenterology and Motility. [Guidelines for the treatment of gastroesophageal reflux disease]. Korean J Gastroenterol 2011;57:57-66. [PMID: 21350318 DOI: 10.4166/kjg.2011.57.2.57] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
45 Zayachkivska O, Havryluk O, Hrycevych N, Bula N, Grushka O, Wallace JL. Cytoprotective effects of hydrogen sulfide in novel rat models of non-erosive esophagitis. PLoS One 2014;9:e110688. [PMID: 25333941 DOI: 10.1371/journal.pone.0110688] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
46 Sharaf RN, Shergill AK, Odze RD, Krinsky ML, Fukami N, Jain R, Appalaneni V, Anderson MA, Ben-Menachem T, Chandrasekhara V. Endoscopic mucosal tissue sampling. Gastrointest Endosc. 2013;78:216-224. [PMID: 23867371 DOI: 10.1016/j.gie.2013.04.167] [Cited by in Crossref: 81] [Cited by in F6Publishing: 55] [Article Influence: 10.1] [Reference Citation Analysis]
47 Chen GW, Xie S, Lian YH, Chen JK. Psychological intervention for auxiliary treatment of non-erosive reflux disease. Shijie Huaren Xiaohua Zazhi 2016; 24(32): 4375-4380 [DOI: 10.11569/wcjd.v24.i32.4375] [Reference Citation Analysis]
48 Pace F, Pace M. The proton pump inhibitor test and the diagnosis of gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol 2010;4:423-7. [PMID: 20678016 DOI: 10.1586/egh.10.38] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
49 Altomare A, Ma J, Guarino MP, Cheng L, Rieder F, Ribolsi M, Fiocchi C, Biancani P, Harnett K, Cicala M. Platelet-activating factor and distinct chemokines are elevated in mucosal biopsies of erosive compared with non-erosive reflux disease patients and controls. Neurogastroenterol Motil 2012;24:943-e463. [PMID: 22734465 DOI: 10.1111/j.1365-2982.2012.01963.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
50 Sun J, Yuan YZ, Hou XH, Zou DW, Lu B, Chen MH, Liu F, Wu KC, Zou XP, Li YQ, Zhou LY. Esomeprazole regimens for reflux symptoms in Chinese patients with chronic gastritis. World J Gastroenterol 2015; 21(22): 6965-6973 [PMID: 26078574 DOI: 10.3748/wjg.v21.i22.6965] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
51 de Bortoli N, Martinucci I, Savarino E, Franchi R, Bertani L, Russo S, Ceccarelli L, Costa F, Bellini M, Blandizzi C. Lower pH values of weakly acidic refluxes as determinants of heartburn perception in gastroesophageal reflux disease patients with normal esophageal acid exposure. Dis Esophagus. 2014;Epub ahead of print. [PMID: 25212408 DOI: 10.1111/dote.12284] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
52 Kandulski A, Wex T, Mönkemüller K, Kuester D, Fry LC, Roessner A, Malfertheiner P. Proteinase-activated receptor-2 in the pathogenesis of gastroesophageal reflux disease. Am J Gastroenterol 2010;105:1934-43. [PMID: 20588261 DOI: 10.1038/ajg.2010.265] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 3.9] [Reference Citation Analysis]
53 Mcalindon ME, Hagenmüller F, Fleischer DE. Fields of Application. In: Keuchel M, Hagenmüller F, Tajiri H, editors. Video Capsule Endoscopy. Berlin: Springer Berlin Heidelberg; 2014. pp. 5-13. [DOI: 10.1007/978-3-662-44062-9_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
54 Fernandes MR, De Oliveira M, Callegari-Jacques SM, Gonçalves GVR, Fornari F. Juice Test for Identification of Nonerosive Reflux Disease in Heartburn Patients. J Neurogastroenterol Motil 2018;24:233-40. [PMID: 29486554 DOI: 10.5056/jnm17077] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
55 Scarpignato C. Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end! Neurogastroenterol Motil. 2012;24:697-704. [PMID: 22783985 DOI: 10.1111/j.1365-2982.2012.01977.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
56 Kopelman Y, Triadafilopoulos G. Endoscopy in the Diagnosis and Management of Motility Disorders. Dig Dis Sci 2011;56:635-54. [DOI: 10.1007/s10620-011-1584-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
57 Yamashita H, Ashida K, Kawaguchi S, Fukuchi T, Nagatani Y, Hasegawa T, Koga H, Eguchi T, Ubukata S, Tanaka T, Ito D. The pathogenesis of persistent non-erosive reflux disease treated with proton-pump inhibitors as measured with the Symptom Index. Esophagus 2015;12:50-6. [DOI: 10.1007/s10388-014-0452-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
58 Allen JI, Katzka D, Robert M, Leontiadis GI. American Gastroenterological Association Institute Technical Review on the Role of Upper Gastrointestinal Biopsy to Evaluate Dyspepsia in the Adult Patient in the Absence of Visible Mucosal Lesions. Gastroenterology 2015;149:1088-118. [DOI: 10.1053/j.gastro.2015.07.040] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
59 Shin WG, Kim HU, Kim SG, Kim GH, Shim KN, Kim JW, Kim JI, Kim JG, Kim JJ, Yim DH, Park SK, Park SH; Korean College of Helicobacter and Upper Gastrointestinal Research. Work productivity and activity impairment in gastroesophageal reflux disease in Korean full-time employees: a multicentre study. Dig Liver Dis 2012;44:286-91. [PMID: 22325831 DOI: 10.1016/j.dld.2011.10.027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
60 Li X, Ding F, Luo P, Yang J, Liu Z, Liu J, Zhang Y, Leng A, Wu K. Study on the Therapeutic Effects of Drug and Cognitive-Behavioral Therapy on Non-Erosive Reflux Disease Patients With Emotional Disorders. Front Psychiatry 2018;9:115. [PMID: 29867593 DOI: 10.3389/fpsyt.2018.00115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
61 Zayachkivska O, Bula N, Khyrivska D, Gavrilyuk E, Wallace JL. Exposure to non-steroid anti-inflammatory drugs (NSAIDs) and suppressing hydrogen sulfide synthesis leads to altered structure and impaired function of the oesophagus and oesophagogastric junction. Inflammopharmacology. 2015;23:91-99. [PMID: 25711289 DOI: 10.1007/s10787-015-0230-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
62 Nagahara A, Shiotani A, Iijima K, Kamada T, Fujiwara Y, Kasugai K, Kato M, Higuchi K. The role of advanced endoscopy in the management of inflammatory digestive diseases (upper gastrointestinal tract). Dig Endosc 2021. [PMID: 33772880 DOI: 10.1111/den.13982] [Reference Citation Analysis]
63 Gao F, Gao Y, Chen X, Qian J, Zhang J. Comparison of oesophageal function tests between Chinese non-erosive reflux disease and reflux hypersensitivity patients. BMC Gastroenterol 2017;17:67. [PMID: 28535800 DOI: 10.1186/s12876-017-0624-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
64 Altomare A, Ma J, Guarino MP, Cheng L, Rieder F, Ribolsi M, Fiocchi C, Biancani P, Harnett K, Cicala M. Platelet-activating factor and distinct chemokines are elevated in mucosal biopsies of erosive compared with non-erosive reflux disease patients and controls. Neurogastroenterol Motil 2012;24:943-e463. [PMID: 22734465 DOI: 10.1111/j.1365-2982.2012.01963.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Kobeissy AA, Hashash JG, Jamali FR, Skoury AM, Haddad R, El-Samad S, Ladki R, Aswad R, Soweid AM. A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease. World J Gastroenterol 2012; 18(19): 2390-2395 [PMID: 22654431 DOI: 10.3748/wjg.v18.i19.2390] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
66 Savarino E, de Bortoli N, De Cassan C, Della Coletta M, Bartolo O, Furnari M, Ottonello A, Marabotto E, Bodini G, Savarino V. The natural history of gastro-esophageal reflux disease: a comprehensive review. Dis Esophagus. 2017;30:1-9. [PMID: 27862680 DOI: 10.1111/dote.12511] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
67 Savarino E, Zentilin P, Savarino V. NERD: an umbrella term including heterogeneous subpopulations. Nat Rev Gastroenterol Hepatol 2013;10:371-80. [DOI: 10.1038/nrgastro.2013.50] [Cited by in Crossref: 122] [Cited by in F6Publishing: 108] [Article Influence: 13.6] [Reference Citation Analysis]
68 Kawada A, Kusano M, Hosaka H, Kuribayashi S, Shimoyama Y, Kawamura O, Akiyama J, Yamada M, Akuzawa M. Increase of transient lower esophageal sphincter relaxation associated with cascade stomach. J Clin Biochem Nutr 2017;60:211-5. [PMID: 28584403 DOI: 10.3164/jcbn.16-53] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
69 Cicala M, Emerenziani S, Guarino MPL, Ribolsi M. Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. World J Gastroenterol 2013; 19(39): 6529-6535 [PMID: 24151377 DOI: 10.3748/wjg.v19.i39.6529] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
70 Losa M, Manz SM, Schindler V, Savarino E, Pohl D. Increased visceral sensitivity, elevated anxiety, and depression levels in patients with functional esophageal disorders and non-erosive reflux disease. Neurogastroenterol Motil 2021;33:e14177. [PMID: 34128293 DOI: 10.1111/nmo.14177] [Reference Citation Analysis]
71 Emerenziani S, Ribolsi M, Pasqualetti P, Cicala M. Measurement of acid exposure of proximal esophagus: a better tool for diagnosing non-erosive reflux disease. Neurogastroenterol Motil 2011;23:711-e324. [PMID: 21595802 DOI: 10.1111/j.1365-2982.2011.01731.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Heading RC. Proton pump inhibitor failure in gastro-oesophageal reflux disease: a perspective aided by the Gartner hype cycle. Clin Med (Lond) 2017;17:132-6. [PMID: 28365622 DOI: 10.7861/clinmedicine.17-2-132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
73 Savarino E, Marabotto E, Zentilin P, Frazzoni M, Sammito G, Bonfanti D, Sconfienza L, Assandri L, Gemignani L, Malesci A. The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. Dig Liver Dis. 2011;43:542-547. [PMID: 21376679 DOI: 10.1016/j.dld.2011.01.016] [Cited by in Crossref: 103] [Cited by in F6Publishing: 92] [Article Influence: 9.4] [Reference Citation Analysis]
74 Quigley EM, Lacy BE. Overlap of functional dyspepsia and GERD--diagnostic and treatment implications. Nat Rev Gastroenterol Hepatol 2013;10:175-86. [PMID: 23296247 DOI: 10.1038/nrgastro.2012.253] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
75 de Bortoli N, Ottonello A, Zerbib F, Sifrim D, Gyawali CP, Savarino E. Between GERD and NERD: the relevance of weakly acidic reflux: Weakly acidic reflux in GERD. Ann N Y Acad Sci 2016;1380:218-29. [DOI: 10.1111/nyas.13169] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
76 Maradey-Romero C, Kale H, Fass R. Nonmedical therapeutic strategies for nonerosive reflux disease. J Clin Gastroenterol. 2014;48:584-589. [PMID: 25000345 DOI: 10.1097/MCG.0000000000000125] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
77 Matsuhashi N, Kudo M, Yoshida N, Murakami K, Kato M, Sanuki T, Oshio A, Joh T, Higuchi K, Haruma K. Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study. J Gastroenterol. 2015;50:1173-1183. [PMID: 25851931 DOI: 10.1007/s00535-015-1073-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
78 Orlando RC, Paterson WG, Harnett KM, Ma J, Behar J, Biancani P, Guarino MP, Altomare A, Cicala M, Cao W. Esophageal disease: updated information on inflammation. Ann N Y Acad Sci. 2011;1232:369-375. [PMID: 21950828 DOI: 10.1111/j.1749-6632.2011.06064.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
79 Melashchenko S. Assessment of gastric acidity by short-duration intragastric pH-monitoring with standardised breakfast in functional and some other dyspepsias. Prz Gastroenterol 2020;15:258-66. [PMID: 33005273 DOI: 10.5114/pg.2020.99041] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
80 Pinto D, Plieschnegger W, Schneider NI, Geppert M, Bordel H, Höss GM, Eherer A, Wolf E, Vieth M, Langner C. Carditis: a relevant marker of gastroesophageal reflux disease. Data from a prospective central European multicenter study on histological and endoscopic diagnosis of esophagitis (histoGERD trial). Diseases of the Esophagus 2018;32. [DOI: 10.1093/dote/doy073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
81 Chen CL, Hsu PI. Current advances in the diagnosis and treatment of nonerosive reflux disease. Gastroenterol Res Pract. 2013;2013:653989. [PMID: 23935610 DOI: 10.1155/2013/653989] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
82 Pauwels A, Broers C, Vanuytsel T, Pardon N, Cocca S, Roman S, Zerbib F, Tack J, Farré R. A reduced esophageal epithelial integrity in a subgroup of healthy individuals increases with proton pump inhibitor therapy. United European Gastroenterol J 2018;6:511-8. [PMID: 29881606 DOI: 10.1177/2050640617749115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
83 Ratin AC, Orso IR. Minimal endoscopic changes in non-erosive reflux disease. Arq Bras Cir Dig 2015;28:20-3. [PMID: 25861063 DOI: 10.1590/S0102-67202015000100006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
84 de Bortoli N, Martinucci I, Bertani L, Russo S, Franchi R, Furnari M, Tolone S, Bodini G, Bolognesi V, Bellini M, Savarino V, Marchi S, Savarino EV. Esophageal testing: What we have so far. World J Gastrointest Pathophysiol 2016; 7(1): 72-85 [PMID: 26909230 DOI: 10.4291/wjgp.v7.i1.72] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
85 de Leone A, Tonini M, Dominici P, Grossi E, Pace F; EMERGE Study Group. The proton pump inhibitor test for gastroesophageal reflux disease: optimal cut-off value and duration. Dig Liver Dis 2010;42:785-90. [PMID: 20452300 DOI: 10.1016/j.dld.2010.04.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]